Physiostim

Executive Summary

Physiostim is a French preclinical Contract Research Organization (CRO) specializing in cardiovascular pharmacology and electrophysiology. Founded in 2007 and headquartered in Bordeaux, the company provides customized, high-value research services spanning drug discovery through clinical development, with a particular emphasis on cardiac safety and efficacy. Physiostim operates GLP-certified facilities and leverages unique human translational models to support biotech and pharmaceutical clients in securing IND applications. Its expertise in cardiovascular preclinical testing positions it as a key partner for companies developing therapies with cardiac implications, especially as regulatory scrutiny on cardiac safety increases. The company’s focus on high-quality, specialized services in a niche area of drug development gives it a competitive edge. With the cardiovascular drug development market expanding, Physiostim is well-positioned to benefit from increased outsourcing of preclinical testing. Key factors for future growth include expansion of its service offerings, potential partnerships with large pharma, and geographical expansion beyond Europe. While the CRO market is competitive, Physiostim’s deep expertise and GLP certification provide a strong foundation. The company’s private status and lack of disclosed funding suggest a stable, self-sustaining operation, though future capital may be needed to scale.

Upcoming Catalysts (preview)

• Q2 2026Signing of Major Contract with Top 20 Pharma60% success
• Q4 2026Expansion of GLP Facility Capacity70% success
• TBDNew Service Offering in Cardio-Oncology Safety Testing50% success